For instance, HH2710, an ERK1/2 inhibitor, was approved by the FDA in September 2019 to treat cancer, including NSCLC with a gene mutant of the MAPK pathway, and subsequently approved by the CDE in March 2020. This evidence concerns the gene MAPK3 and cancer.